title: Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.
abstract: Immunologic data supporting immediate antiretroviral therapy in primary human immunodeficiency virus type 1 (HIV-1) infection are emerging; however, clinical benefit has not been demonstrated. The clinical and virologic course of 47 patients who were enrolled from September 1993 through June 1996 and who were not initially treated with potent therapy was compared with the course of 20 patients who immediately began therapy with zidovudine, lamivudine, and indinavir. Demographic and baseline laboratory data were comparable. During 78 weeks of follow-up, the early-treatment cohort showed a reduced frequency of opportunistic infections (5% vs. 21.3%; relative risk, 0.11; P=.02), less frequent progression to AIDS (13% vs. 0%), and significantly less frequent nonopportunistic mucocutaneous disorders and respiratory infections (P<.01). Plasma HIV-1 RNA levels were <50 copies/mL in all patients who continued therapy; however, after 9--12 months, HIV-1 remained detectable in latently infected CD4(+) T cells and in lymph node mononuclear cells. Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and reduced progression to AIDS.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Berrey
authors.forename: T
authors.initials: T
authors.lastname: Schacker
authors.forename: A C
authors.initials: AC
authors.lastname: Collier
authors.forename: T
authors.initials: T
authors.lastname: Shea
authors.forename: S J
authors.initials: SJ
authors.lastname: Brodie
authors.forename: D
authors.initials: D
authors.lastname: Mayers
authors.forename: R
authors.initials: R
authors.lastname: Coombs
authors.forename: J
authors.initials: J
authors.lastname: Krieger
authors.forename: T W
authors.initials: TW
authors.lastname: Chun
authors.forename: A
authors.initials: A
authors.lastname: Fauci
authors.forename: S G
authors.initials: SG
authors.lastname: Self
authors.forename: L
authors.initials: L
authors.lastname: Corey
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000453:epidemiology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D004279:DNA, Viral / Q000032:analysis; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000821:virology; D008297:Male; D010349:Patient Compliance; D012367:RNA, Viral / Q000097:blood
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral